The Influence of Obesity on Small Bowel Capsule Endoscopy
Table 1
The patients’ characteristics ().
Males
183 (53.8)
Age (yrs)
49 (31-69)
Preparation (15 mg mosapride)
283 (83.2)
Height (cm)
163 (155.3-170)
Weight (kg)
56 (48.1-65)
BMI (kg/m2)
21 (18.8-23.8)
54 (15.9)
9 (2.6)
Objective of the examination
Obscure GI bleeding
115 (33.8)
IBD
93 (27.4)
IBD suspected
48 (14.1)
Tumor
28 (8.2)
Anemia
18 (5.3)
Others
38 (11.2)
Comorbidities
Hypertension
101 (29.7)
Heart disease
63 (18.5)
Diabetes mellitus
45 (13.2)
Liver cirrhosis
17 (5)
Hemodialysis
14 (4.1)
Diarrhea-predominant IBS
16 (4.7)
Crohn’s disease
58 (17.1)
Constipation
36 (10.6)
Laboratory data
Hemoglobin (g/dL)
11.9 (9.5–13.7)
Platelet (×1044/μL)
23 (18.3–29.6)
Albumin (g/dL)
3.9 (3.3–4.4)
BUN (mg/dL)
13.3 (10.2–21)
Cr (mg/dL)
0.79 (0.65–0.98)
Intestinal transit time
ETT (sec)
3 (2–8)
GTT (min)
14 (8–32)
SBTT (min)
216.5 (155–309)
Inpatient examination
136 (40)
Urgent examination
22 (6.5)
The data are median (interquartile range) or number (%) of patients. BMI: body mass index; BUN: blood urea nitrogen; Cr: creatinine; ETT: esophagus transit time; GI: gastrointestinal; GTT: gastric transit time; IBD: inflammatory bowel disease; IBS: irritable bowel syndrome; SBTT: small bowel transit time.
